Agendia Genomic Tests (MammaPrint, BluePrint & TargetPrint) Among Highlights of San Antonio Breast Cancer Symposium
Podium Presentations and Ten Scientific Posters Focus Cancer MDs’ Attention Read More
Agendia Announces Presentation of Data Highlighting Symphony Suite of Genomic tests (MammaPrint, BluePrint, and TargetPrint) at San Antonio Breast Cancer Symposium
Ten Scientific Posters Document Study Results on Second-Generation Symphony Suite, Read More
Prospective Cost-Effectiveness Analysis of Genomic Profiling in Breast Cancer
PUBLICATION: European Journal of Cancer. December 2013, Volume 49, Issue Read More
Performance Characteristics of the MammaPrint® Breast Cancer Diagnostic Gene Signature
PUBLICATION: PERSONALIZED MEDICINE VOL. 10, NO. 8 | 17 Oct Read More
Multiple International Breast Cancer Guidelines Confirm Use of Agendia Tests for Prognostic, Predictive Information in Cancer Treatment Decisions
Important Role of Molecular Subtyping in Determining the Need for Read More
Researchers Identify Splice Variant of Breast Cancer Gene that Can Mask Risk of Recurrence
‘High Risk’ Patients with Unusual Hormone Receptors May Be Undertreated Read More
Estrogen Receptor Splice Variants as a Potential Source of False-Positive Estrogen Receptor Status in Breast Cancer Diagnostics
PUBLICATION: Breast Cancer Res Treat (2013) 140:475–484 DOI 10.1007/s10549-013-2648-1 AUTHORS: Read More
Potential Impact of the 70-gene Signature in the Choice of Adjuvant Systemic Treatment for ER Positive, HER2 Negative Tumors: a Single Institution Experience
PUBLICATION: Breast. 2013 Aug;22(4):419-24. doi: 10.1016/j.breast.2013.03.013. Epub 2013 May 3. Read More
MammaPrint Pre-Screen Algorithm (MPA) Reduces Chemotherapy in Patients with Early-Stage Breast Cancer
PUBLICATION: S Afr Med J. 2013 Jul 3;103(8):522-6. doi: 10.7196/samj.7223. Read More
Association Between Genomic Recurrence Risk and Well-Being Among Breast Cancer Patients
PUBLICATION: BMC Cancer. 2013 Jun 18;13:295. doi: 10.1186/1471-2407-13-295. AUTHORS: Retèl Read More
